[Clinical analysis and treatment of @entity263 with bone XXXX ].

@entity172 @entity1 @entity263 @entity3 @entity1260 @entity204 @entity420
We carried out a clinical analysis of @entity263 with bone @entity3 in 141 cases of @entity263 treated between 1965 and 1984. Among these, there were 64 cases of stage D, 45.4% and 55 cases of bone @entity3 at the first visit. Stage D cases were mainly treated with @entity172 . Poorly differentiated @entity420 was observed in 62% of the stage D cases. Elevated pretreatment levels of serum acid phosphatase in the cases of bone @entity3 were found in 47.8-71.4% of @entity1 with poorly differentiated @entity420 . Elevated acid phosphatase levels were also normalized by @entity172 administration in over 60% of cases, regardless of the degree of differentiation. Also, clinical efficacy of @entity172 was observed in more than 80% of stage D cases with any degree of differentiation. The most frequent clinically observed metastatic site was bone. Pain-relieving effects of @entity172 , radiation and @entity1260 were observed in 76.3%, 92.3% and 70%, of @entity1 , respectively. The cause of @entity204 in stage D @entity1 was mainly aggravation of metastatic lesions. The period for which @entity172 was effective was 45 months on average in cases who died at stage D. The period from reactivation to @entity204 averaged 16 months, while the period from the beginning of treatment to @entity204 in cases unresponsive to @entity172 was only 11 months on average.
